Collaboration Empowers a Synergistic Win | Apeloa signs strategic agreement with Suzhou Zelgen Biopharmaceutical Co. Ltd.

Recently, senior executives from Suzhou Zelgen Biopharmaceutical Co., Ltd. (hereinafter referred to as Zelgen) paid a visit to Apeloa for extensive discussions on long-term collaboration for CDMO projects. Subsequently, a strategic agreement was signed between the two companies. Sheng Zelin, the Chairman and General Manager of Zelgen, along with his senior management team, met with Zhu Fangmeng, the Party Secretary and Chairman of Apeloa, and other key leaders who attended the event.?

? At the meeting, Zhu Fangmeng extended a warm welcome to everyone and expressed his enthusiasm for the collaboration. He emphasized that Zelgen has been a leading force in the field of innovative drug research and development in China for many years, particularly focused on the exploration of new chemical and biological drugs in various fields such as oncology.?Furthermore, through continuous increases in R&D investment, Apeloa has accelerated construction to expand production capacity and strengthen its system management capabilities. Apeloa now has the ability to provide one-stop R&D and production services for the entire life cycle needs of global innovative drug customers. The two sides will now take this strategic agreement as an opportunity to jointly explore and achieve mutually beneficial cooperation.?

Dr. Sheng Zelin, Chairman and General Manager of Zelgen Biopharmacetical Co., Ltd., praised Apeloa for its leading-edge API and intermediate production facilities, R&D capabilities, and quality management and EHS control systems, among other qualities. These advancements give Apeloa a robust outsourcing platform for both international and domestic pharmaceutical enterprises. It is believed that collaborating with Apeloa will further ensure a stable and high-quality supply of APIs, establish a broader strategic relationship, and provide patients with more high-quality drug options.?

Sheng Zelin and Zhu Fangmeng officially signed the Strategic Cooperation Framework Agreement on behalf of their respective organizations and engaged in comprehensive discussions on cooperation matters.??

Prior to the meeting, Zelgen’s senior management team visited Apeloa’s analytical testing center, the production workshop of the CDMO's global innovative drug service, and the high-potency API workshop. Apeloa’s advanced production equipment, stringent management practices, and operational excellence have received unanimous praise and appreciation by customers.

About Zelgen Biopharmaceutical Co., Ltd. (688266. SH）?

Zelgen is an innovation-driven company dedicated to the research, development, and manufacturing of chemical and biological drugs. Their focus spans multiple therapeutic areas, including oncology, bleeding and blood diseases, immunoinflammatory diseases, and hepatobiliary diseases. With a strong commitment to the development and production of innovative drugs with global independent intellectual property rights, Zelgen aims to provide safe, effective, and affordable treatments to meet vast clinical need at home and worldwide.?

Since its establishment, Zelgen has pursued a developmental strategy centered around independent innovation, improvement, and re-innovation. Their drug candidates target tumors, bleeding and blood diseases, immunoinflammatory diseases and hepatobiliary diseases, filling the domestic gap in these areas and addressing unmet clinical needs. The company consistently focuses on both major and rare diseases, carefully monitoring the specific effects of their drugs under development. The company focuses on both major and rare diseases, and pays attention to the leading, broad-spectrum, and specific effects of drugs under development, forming a differentiated competitive advantage through their product pipeline.?

Zelgen has established three R&D centers and three GMP production lines. Their global development framework focuses on technological and resource advantages in multiple locations such as Kunshan, Jiangsu, Shanghai, Zhanjiang, and California, USA. By maximizing the R&D and industrialization potential in both small molecule and biological macromolecule drugs, Zelgen has the capacity to bring much innovation to the pharmaceutical world.?

?